Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab da soli e con chemioterapia combinata per il trattamento del linfoma diffuso a grandi cellule B del centro non germinale di nuova diagnosi, studio Smart Stop

5 ottobre 2026 aggiornato da: M.D. Anderson Cancer Center

Smart Stop: uno studio di fase II su rituximab, lenalidomide, acalabrutinib, tafasitamab prima e con la chemioterapia standard per i pazienti con DLBCL di nuova diagnosi

This phase II trial studies the effect of rituximab, lenalidomide, acalabrutinib, tafasitamab alone and in combination with chemotherapy in treating patients with newly diagnosed non-germinal center diffuse large B-cell lymphoma. Rituximab and tafasitamab are monoclonal antibodies that may interfere with the ability of tumor cells to grow and spread. Acalabrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, cyclophosphamide, doxorubicin, and vincristine, and work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Anti-inflammatory drugs, such as prednisone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Giving rituximab, lenalidomide, acalabrutinib, tafasitamab alone and with combination chemotherapy may help control non-germinal center diffuse large B-cell lymphoma.

Panoramica dello studio

Descrizione dettagliata

PRIMARY OBJECTIVES:

I. To determine the overall response rate at the end of 4 cycles of therapy with rituximab, lenalidomide, acalabrutinib, tafasitamab in patients with high risk newly diagnosed non-germinal center B-cell (GCB) diffuse large B-cell lymphoma (DLBCL).

II. To determine the complete response rate at the end of 10 cycles of therapy with rituximab, lenalidomide, acalabrutinib, tafasitamab and chemotherapy (cyclophosphamide-hydroxydaunorubicin-oncovin-prednisone [CHOP]) in patients with high risk newly diagnosed non-GCB DLBCL.

SECONDARY OBJECTIVES:

I. To determine the overall response rate, survival outcomes (progression free and overall survival), and safety of rituximab, lenalidomide, acalabrutinib, tafasitamab and chemotherapy (CHOP) in patients with high risk newly diagnosed non-GCB DLBCL.

II. To evaluate the outcomes of patients who receive 10 cycles of rituximab, lenalidomide, acalabrutinib, tafasitamab with 6 concurrent cycles of CHOP in contrast to patients who receive a response adapted 2 concurrent cycles of CHOP in cohort 1.

III. To evaluate the outcomes of patients who receive 10 cycles of rituximab, lenalidomide, acalabrutinib, tafasitamab with 6 concurrent cycles of CHOP in contrast to patients who receive a response adapted 0 concurrent cycles of CHOP in cohort 2.

EXPLORATORY OBJECTIVE:

I. To evaluate the baseline and therapy induced changes in the profile of mutations, gene expression, minimal residual disease circulating tumor deoxyribonucleic acid (ctDNA) levels, immune cell subsets, in patients with newly diagnosed non-GCB DLBCL.

OUTLINE:

COHORT I (SMART STOP): Patients receive rituximab intravenously (IV) over 4-6 hours on day 1, acalabrutinib orally (PO) twice daily (BID) on days 1-21, lenalidomide once daily (QD) on days 1-10, and tafasitamab IV over 2 hours on days 1, 8, and 15. Treatments repeat every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.

COHORT II (uLTRA-CHOP): Patients who achieve a complete response to the Smart Stop in Cohort I, receive rituximab IV over 4-6 hours on day 1, acalabrutinib PO BID on days 1-21, lenalidomide QD on days 1-10, and tafasitamab IV over 2 hours on days 1, 8, and 15. Treatments repeat every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive cyclophosphamide IV over 1 hour, doxorubicin hydrochloride IV over 15 minutes, vincristine IV over 15 minutes on day 1, and prednisone PO QD on days 1-5. Treatments repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve less than a complete response, receive rituximab IV over 4-6 hours on day 1, acalabrutinib PO BID on days 1-21, lenalidomide QD on days 1-10, and tafasitamab IV over 2 hours on days 1, 8, and 15. Patients also receive cyclophosphamide IV over 1 hour, doxorubicin hydrochloride IV over 15 minutes, vincristine IV over 15 minutes on day 1, and prednisone PO QD on days 1-5. Treatments repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 1 year, then every 4 months for 1 year.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

62

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Texas
      • Houston, Texas, Stati Uniti, 77030
        • M D Anderson Cancer Center

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Histopathologically confirmed diagnosis of DLBCL.

  2. No prior treatment except a prior limited-field radiotherapy, a short course of glucocorticoids ≤50mg daily of prednisone equivalent which must be no more than 4 days in duration and cease prior to day 1 of cycle 1, and/or 1 dose of cyclophosphamide 750mg/m2 for an urgent lymphoma related problem at diagnosis (e.g. epidural cord compression, superior vena cava syndrome).

  3. Age ≥ 18 years and able to provide informed consent.

  4. Participants must have bi-dimensional measurable disease, as defined as radiographically apparent disease with the longest dimension of ≥1.5cm.

  5. Participants with performance status of ≤3 (3 only allowed if decline in status is deemed related to lymphoma and felt potentially reversible by the treating physician).

  6. Serum bilirubin <1.5x ULN except in participants with Gilbert's syndrome as defined by > 80% unconjugated bilirubin who must have a serum bilirubin of <4x ULN; AST (SGOT) and ALT (SGPT) ≤ 3x ULN or < 5x ULN if hepatic metastases are present; ANC >1000/mm3 and platelets >100,000/mm3 unless deemed related to lymphoma involvement in the bone marrow and felt potentially reversible by the treating physician.

  7. Renal function assessed by calculated creatinine clearance:

    a. Calculated creatinine clearance ≥ 30ml/min by Cockcroft-Gault formula. See section below, "Dosing Regimen", regarding lenalidomide dose adjustment for calculated creatinine clearance ≥ 30ml/min and < 60ml/min.

  8. Participants must be willing to receive transfusions of blood products.

  9. All study participants must be registered into the mandatory Revlimid REMS® program, and be willing and able to comply with the requirements of the REMS® program.

  10. Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) at screening and must adhere to the scheduled pregnancy testing as required in the Revlimid REMS® program.

  11. Women of childbearing potential and men who are sexually active with a woman of childbearing potential must be practicing a highly effective method of during and after the study (12 months after study drug for women and 3 months after study drug for men), consistent with local regulations regarding the use of birth control methods for participants participating in this clinical study. Men must agree to not donate sperm during and for up to 3 months after their conclusion of therapy on study.

  12. Able to take aspirin (81 mg) daily or alternative therapy as prophylactic anticoagulation

Exclusion Criteria:

  1. Any serious medical condition including but not limited to uncontrolled hypertension, uncontrolled congestive heart failure within past 6 months prior to screening (Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification), uncontrolled or symptomatic arrhythmias with corrected QT interval (QTc) > 480 msec at screening, uncontrolled diabetes mellitus, active/symptomatic coronary artery disease, COPD, LVEF less than 40%, renal failure, uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura active infection, history of invasive fungal infection, moderate to severe hepatic disease (Child Pugh Class B or C), active hemorrhage, laboratory abnormality, or psychiatric illness that, in the investigators opinion places the participant at unacceptable risk and would prevent the subject from signing the informed consent form. Participants with history of cardiac arrhythmias should have cardiac evaluation and clearance.
  2. Pregnant or lactating females.
  3. Known hypersensitivity to lenalidomide or thalidomide, acalabrutinib, tafasitamab, rituximab, vincristine, doxorubicin, cyclophosphamide, or prednisone.
  4. Known HIV infection. Hepatitis B or C serologic status: subjects who are hepatitis B core antibody (anti-HBc) positive and who are hepatitis B surface antigen (HBsAg) negative will need to have a negative DNA polymerase chain reaction (PCR) and must be willing to undergo DNA PCR testing during the study to be eligible. Those who are HBsAg positive or hepatitis B DNA PCR positive will be excluded. Participants who are hepatitis C antibody positive will need to have a negative DNA PCR result to be eligible. Those who are hepatitis C DNA PCR positive will be excluded.
  5. All participants with known central nervous system involvement with lymphoma.
  6. Diagnosis of prior malignancy within the past 2 years with the exception of successfully treated basal cell carcinoma, squamous cell carcinoma of the skin, carcinoma "in situ" of the cervix or breast. History of other malignancies are allowed if in remission (including prostate cancer participants in remission from radiation therapy, surgery or brachytherapy), not actively being treated, with a life expectancy > 3 years.
  7. Significant neuropathy (Grades 2 or Grade 1 with pain) within 14 days prior to enrollment
  8. Contraindication to any of the required concomitant drugs or supportive treatments or intolerance to hydration due to preexisting pulmonary or cardiac impairment including pleural effusion requiring thoracentesis or ascites requiring paracentesis not due to lymphoma.
  9. Participants with active pulmonary embolism or deep vein thrombosis (diagnosed within 30 days of study enrollment).
  10. Participants with severe bradycardia (heart rate <40 bpm, hypotension, light-headedness, syncope).
  11. Major surgery within 4 weeks of study entry, or wound that is not healed from prior surgery or trauma.
  12. History of stroke or intracranial hemorrhage within 6 months prior to study entry.
  13. Requires anticoagulation with warfarin or equivalent vitamin K antagonists.
  14. Requires chronic treatment with strong CYP3A inhibitors.
  15. Vaccinated with live, attenuated vaccines within 4 weeks of study entry.
  16. Active bleeding or history of bleeding diathesis (eg, hemophilia or von Willebrand disease).
  17. Uncontrolled AIHA (autoimmune hemolytic anemia) or ITP (idiopathic thrombocytopenic purpura).
  18. Presence of a gastrointestinal ulcer diagnosed by endoscopy within 3 months before screening.
  19. Prothrombin time (PT)/INR or aPTT (in the absence of lupus anticoagulant) >2x ULN.
  20. Requires treatment with proton pump inhibitors (eg, omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole). Note: Subjects receiving proton pump inhibitors who switch to H2-receptor antagonists or antacids are eligible for enrollment to this study.
  21. Concurrent participation in another therapeutic clinical trial.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione sequenziale
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Treatment (uLTRA, CHOP)

COHORT I (SMART STOP): Patients receive rituximab IV over 4-6 hours on day 1, acalabrutinib PO BID on days 1-21, lenalidomide QD on days 1-10, and tafasitamab IV over 2 hours on days 1, 8, and 15. Treatments repeat every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.

COHORT II (uLTRA-CHOP): Patients who achieve a complete response to the Smart Stop in Cohort I, receive rituximab IV over 4-6 hours on day 1, acalabrutinib PO BID on days 1-21, lenalidomide QD on days 1-10, and tafasitamab IV over 2 hours on days 1, 8, and 15. Treatments repeat every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive cyclophosphamide IV over 1 hour, doxorubicin hydrochloride IV over 15 minutes, vincristine IV over 15 minutes on day 1, and prednisone PO QD on days 1-5. Treatments repeat every 21 days for up to 6 cycles in the absence of disease progr

Given IV

Altri nomi:
  • Cytoxan
  • CTX
  • (-)-ciclofosfamide
  • 2H-1,3,2-ossazafosforina, 2-[bis(2-cloroetil)ammino]tetraidro-, 2-ossido, monoidrato
  • Carloxan
  • Ciclofosfamidica
  • Ciclofosfamide
  • Ciclossale
  • Clafen
  • Clafene
  • CP monoidrato
  • Cella CYCLO
  • Cicloblastina
  • Ciclofosfame
  • Ciclofosfamide monoidrato
  • Ciclofosfamidum
  • Ciclofosfano
  • Ciclofosfanum
  • Ciclostina
  • Citofosfano
  • Fosfaseron
  • Genoxal
  • Genuxale
  • Ledossina
  • Mitoxan
  • Neosar
  • Revimmune
  • Syklofosfamide
  • WR-138719

Given IV

Altri nomi:
  • Adriamicina
  • 5,12-naftacenedione, 10-[(3-ammino-2,3,6-trideossi-alfa-L-lisso-esopiranosil)ossi]-7,8, 9,10-tetraidro-6,8,11-triidrossi -8-(idrossiacetil)-1-metossi-, cloridrato, (8S-cis)- (9CI)
  • ADM
  • Adriacin
  • Adriamicina cloridrato
  • Adriamicina PFS
  • Adriamicina RDF
  • ADRIAMICINA, CLORIDRATO
  • Adriblastina
  • Adrimedac
  • Cloridrato di Doxorrubicina
  • DOX
  • DOXO-CELL
  • Doxolem
  • Doxorubicina cloridrato
  • Doxorubicina.HCl
  • Doxorubina
  • Farmiblastina
  • FI 106
  • FI-106
  • idrossidaunorubicina
  • Rubex

Given PO

Altri nomi:
  • Deltason
  • Orasone
  • .delta.1-Cortisone
  • 1,2-deidrocortisone
  • Adason
  • Cortancyl
  • Dacortin
  • DeCortin
  • Decortisil
  • Decorton
  • Delta 1-cortisone
  • Delta-cupola
  • Deltacortene
  • Deltacortisone
  • Deltadeidrocortisone
  • Deltisone
  • Deltra
  • Econosone
  • Lisacort
  • Meprosona-F
  • Metacortandracina
  • Meticorten
  • Ofisolona
  • Panafcort
  • Panasol-S
  • Paracorto
  • Perrigo Prednisone
  • PRED
  • Predicor
  • Predicorten
  • Prednicen-M
  • Prednicort
  • Prednidib
  • Prednilonga
  • Prednimento
  • Prednisone Intensolo
  • Prednisonum
  • Prednitone
  • Promifen
  • Rayos
  • Servisone
  • SK-Prednisone

Given PO

Altri nomi:
  • CC-5013
  • Revimid
  • CC5013
  • CDC 501

Given IV

Altri nomi:
  • Rituxan
  • MabThera
  • PAB 798
  • BI 695500
  • Anticorpo monoclonale C2B8
  • Anticorpo chimerico anti-CD20
  • CT-P10
  • IDEC-102
  • IDEC-C2B8
  • Anticorpo monoclonale IDEC-C2B8
  • PF-05280586
  • Rituximab ABBS
  • Rituximab biosimilare ABP 798
  • Rituximab Biosimilare BI 695500
  • Rituximab Biosimilare CT-P10
  • Rituximab biosimilare GB241
  • Rituximab biosimilare IBI301
  • Rituximab biosimilare JHL1101
  • Rituximab biosimilare PF-05280586
  • Rituximab biosimilare RTXM83
  • Rituximab biosimilare SAIT101
  • Rituximab biosimilare SIBP-02
  • rituximab biosimilare TQB2303
  • rituximab-abs
  • RTXM83
  • Truxima

Given IV

Altri nomi:
  • Videoregistratore
  • Leurocristina
  • Vincristina

Given PO

Altri nomi:
  • Calquenza
  • ACP-196
  • Bruton tirosina chinasi inibitore ACP-196

Given IV

Altri nomi:
  • MOR208
  • Monjuvi
  • MOR-00208
  • MOR00208
  • Tafasitamab-cxix
  • XmAb5574
  • Immunoglobulina, anti-(antigene Cd19 umano) (catena pesante monoclonale MOR00208 di musculus umano), disolfuro con catena monoclonale di musculus umano MOR00208 .Kappa., dimero

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Overall response rate
Lasso di tempo: At the end of 4 cycles of therapy with rituximab, lenalidomide, acalabrutinib, tafasitamab (each cycle = 21 days)

The response rate and exact 95% confidence intervals will be calculated.

At the end of 4 cycles of therapy with rituximab, lenalidomide, acalabrutinib, tafasitamab (each cycle = 21 days)
Complete response rate
Lasso di tempo: At the end of 10 cycles of therapy with rituximab, lenalidomide, acalabrutinib, tafasitamab and chemotherapy (each cycle = 21 days)

The response rate and exact 95% confidence intervals will be calculated.

At the end of 10 cycles of therapy with rituximab, lenalidomide, acalabrutinib, tafasitamab and chemotherapy (each cycle = 21 days)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Incidence of adverse events (AEs)
Lasso di tempo: Up to 30 days post-treatment

The unacceptable toxicity rate and exact 95% confidence intervals will be calculated. AE data will be summarized by frequency tables for all patient

Up to 30 days post-treatment
Progression free survival
Lasso di tempo: From study entry to objective disease progression or death from any cause, whichever occurs first, assessed up to 2 years post-treatment

Will be estimated using the method of Kaplan and Meier.

From study entry to objective disease progression or death from any cause, whichever occurs first, assessed up to 2 years post-treatment
Overall survival
Lasso di tempo: Time between study entry and death from any cause, assessed up to 2 years post-treatment

Will be estimated using the method of Kaplan and Meier.

Time between study entry and death from any cause, assessed up to 2 years post-treatment

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Jason Westin, MD, M.D. Anderson Cancer Center

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

3 marzo 2022

Completamento primario (Stimato)

16 gennaio 2027

Completamento dello studio (Stimato)

16 gennaio 2027

Date di iscrizione allo studio

Primo inviato

10 giugno 2021

Primo inviato che soddisfa i criteri di controllo qualità

23 luglio 2021

Primo Inserito (Effettivo)

27 luglio 2021

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

6 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

5 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 2021-0046
  • NCI-2021-04298 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
  • 2021-0046 (Altro identificatore: M D Anderson Cancer Center)

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi